Novel SHP2 degrader SHP2-D26 in combination with the EGFR inhibitor osimertinib (AZD9291) could overcome osimertinib resistance in NSCLC by reducing MCL-1 expression [38]. The gene discussed is PTPN11; the disease is non-small cell lung carcinoma.